Philips receives CE mark for PET/MRI system — first new modality
in 10 years
24 Jan 2011
Royal Philips Electronics has been awarded the CE mark for its
whole-body PET/MR imaging system, the Ingenuity TF PET/MR system.
This new combined imaging system, the industry’s first commercially available, is
also Philips first new modality in ten years. It
integrates the molecular imaging capabilities of PET (positron
emission tomography) with the superior soft tissue contrast of MR
(magnetic resonance) to image disease cells as they proliferate in
The system is not yet available commercially in the US, which tends
to take longer to approve new technology.
Since the Ingenuity TF PET and MR scanners are placed only three
meters apart and the patient table rotates to allow the patient to
be scanned by each modality, the system can also acquire separate
PET and MR images.
The combined PET/MRI scanner was developed in just over a year by
Philips with the Translational and Molecular Imaging Institute,
Department of Radiology, Mount Sinai School of Medicine, New York.
MTB Europe reported on the inauguration of the second, and
Europe's first, scanner at the University Hospitals of Geneva in May
scanner opens new frontier in medical imaging). The Institute of
Radiopharmacy, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden,
Germany has also installed one and more are expected this year.
Philips has also
developed a novel delivery system — the complete scanner suite can
be delivered ready-to-use in a 48 tonne container, needing only a
suitable foundation and connection to utilities.
Clinicians anticipate using the Ingenuity TF PET/MR to screen
patients at high-risk for heart disease to ultimately treat diseased
cells prior to the formation of dangerous coronary plaques. The
system may also be used to scan patients to detect tumour
Since the Ingenuity TF PET/MR provides the best of Astonish TF
PET and 3T MR, it is also possible to track whether a drug is
reaching a tumour or plaque and monitor efficacy on a potential
cellular level. In addition to greater visualization of disease
process, the system can also produce up to 70% less ionizing
radiation than PET/CT.
The future of personalized medicine
The combination of advances in high resolution MR and the ability
to combine MR and PET into one whole body system has lead healthcare
professionals to believe that the Ingenuity TF PET/MR will help
identify disease sooner and make personalized medicine a reality.
“It’s rare to develop a modality that completely revolutionizes
imaging; usually, companies can only strive for clearer images at a
lower dose. With the Ingenuity TF PET/MR, researchers are
experiencing breakthroughs on multiple fronts.
"They are able to effectively image the prostate for the first
time and detect deadly cancers in organs such as the pancreas at a
significantly earlier stage,” said Dominic Smith, vice president of
marketing, Computed Tomography and Nuclear Medicine for Philips
“The Ingenuity TF PET/MR provides researchers and clinicians an
unprecedented opportunity to make earlier diagnoses and personalize
treatments for oncology and cardiology.”
Video Prof. Osman Ratib talks about the